Clinical trials: Atrophy of Vagina
Vaginal Atrophy
Evaluation of VagiVital® for Treatment of Vaginal Atrophy
An open study to evaluate the ability of VagiVital in reducing the severity of moderate to severe symptoms of vaginal atrophy for women under treatment on adjuvant aromatase inhibitor therapy.
- Trial name
- NCT03998722
- Testing
- Vagivital
- Where
- Sweden
- Volunteers
- 31 people
- Sponsor
- PepTonic Medical AB
Postmenopausal Vulvovaginal Atrophy
A Clinical Study of INTRAROSA® (Prasterone) Vaginal Inserts in Postmenopausal Vulvovaginal Atrophy
This study is a phase III which includes two treatment phases. The phase 1 study is a multi-center, randomized, double-blind, placebo- controlled, parallel group that provide primary efficacy and safety data.
- Trial name
- NCT04982692
- Testing
- intravaginal prasterone
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Lee's Pharmaceutical Limited
Vaginal Atrophy, Genitourinary Disease
Effect of Hybrid Laser 10600+1540 nm on GSM
The primary objective of the study is to clinically confirm, by comparison with a control group, the performance of the 10600 +1540 nm laser in the improvement of atrophic vaginal epithelium at 3 months after the last laser…
- Trial name
- NCT03956563
- Testing
- Youlaser MT Group 2, Youlaser MT Group 1
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Quanta System, S.p.A.
Vulvo Vaginal Atrophy
Regenerative Treatment of Female Genital Atrophy
Vulvovaginal health is a key aspect of active and healthy aging for all women. Hormonal deprivation that occurs during menopause significantly affects the anatomy and function of urogenital tissues, leading to their atrophy.
- Trial name
- RETREAT-FUGA (NCT07306611)
- Testing
- Mesotherapy with Autologous Platelet-Rich Plasma (PRP) to vulvovaginal area, Mesotherapy with saline solution, Platelet-Poor Plasma Gel
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- AndreiaAntunes
Breast Cancer
Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment
Many studies have shown that locoregional treatment (surgery, radiotherapy) and systemic treatment (endocrine therapy and chemotherapy) for breast cancer (BC) may impact sexuality by causing physical and/or psychological damages.
- Trial name
- EPIONE-01 (NCT04713917)
- Testing
- Hyaluronique Acid Gel, Laser CO2, Hyaluronique Acid Injection
- Where
- France
- Volunteers
- 330 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Genitourinary Syndrome of Menopause (GSM)
Bipolar Radiofrequency for Genitourinary Syndrome of Menopause
This randomized, sham-controlled clinical trial aims to evaluate the efficacy and safety of bipolar radiofrequency in the treatment of genitourinary syndrome of menopause (GSM) in postmenopausal women.
- Trial name
- BRF-GSM (NCT07419035)
- Testing
- Active bipolar radiofrequency therapy
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Castilla-La Mancha
Vaginal Atrophy
Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment
Postmenopausal hypoestrogenism may determine genital atrophy, which may be accompanied by a non-specific inflammatory process and may hinder or even prevent sexual intercourse.
- Trial name
- NCT04717245
- Testing
- Promestriene Vaginal, Fractional CO2 LASER, Microablative Fractional radiofrequency
- Where
- Brazil
- Volunteers
- 75 people
- Sponsor
- University of Sao Paulo General Hospital
Atrophy, Vaginal Diseases
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.
- Trial name
- NCT01585558
- Testing
- Ospemifene (Dose 1), Ospemifene (Dose 2)
- Volunteers
- 180 people
- Sponsor
- Shionogi
Vulvovaginal Atrophy
Performance and Safety of Hyalo Gyn Gel on the Treatment of Vaginal Atrophy in Postmenopausal Women
This clinical investigation evaluates the performance and safety of Hyalo Gyn, a hyaluronic acid derivative based vaginal gel for the treatment of symptoms of vulvo-vaginal atrophy in post-menopausal women.
- Trial name
- NCT04355403
- Testing
- Hyalo Gyn gel in prefilled applicators
- Where
- 2 sites in Slovakia
- Volunteers
- 80 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Vaginal Atrophy
A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair
1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction.
- Trial name
- NCT04492176
- Testing
- CO2 fractional laser（ACUPULSE,Lumenis）
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Dyspareunia
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
- Trial name
- NCT05617820
- Testing
- Estradiol, Imvexxy
- Where
- 48 sites in United States, El Salvador and 1 more
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA